• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Genzyme Expands UK Site


February 18, 2010.

US biotech Genzyme has announced a major expansion of its European research facility on the Cambridge (UK) Science Park. The building and refurbishment programme will more than double scale of the site, which currently employs around 90 people. Alongside the expansion programme, the company is hiring a number of new senior people to be based at the site, including a Medical Director, Oncology, and a Vice President, Regulatory Affairs.
The Cambridge facility was Genzyme's first dedicated R&D facility in Europe; it conducts research into advanced treatments for cancer, kidney diseases and immune-mediated diseases and manages a range of clinical trials. Peter Harris, the company's Vice President, Clinical Research, and Cambridge site head, commented: "We are establishing ourselves as the "go-to" place for drug development in oncology, renal and cell therapies for Genzyme Europe.""